<Back to Therapeutic Areas

<Back to Menu

Respiratory

IME/CME for HCPs

GSK identifies and funds innovative, high-quality, independent third-party educational initiatives that are designed to close healthcare professional (HCP) educational, quality, and performance gaps to improve patient health and quality of life. GSK provides financial support for independent medical education (IME) for HCPs, including certified continuing medical education (CME, CE), with a grant.

Educational providers are fully compliant with the ACCME (and other nationally recognized accrediting body) standards for commercial support and design and deliver all activities (including content, faculty, speakers, and educational materials) independent from GSK control, influence, and involvement.

These initiatives offer opportunities for continual learning regarding educational topics and are free for learners to access. For more information about any of these initiatives, please click the link to be directed to the educational provider's website. All questions about these activities should be directed to the educational provider listed for each activity, not to GSK, as these are not GSK initiatives.


Hypereosinophilic Syndrome

D is for Diagnosis Rare Disorders Respiratory

Expiration Date: November 30, 2022

Educational Provider: Physicians’ Education Resource, LLC


Chronic Rhinosinusitis with Nasal Polyps

Novel Therapies for Chronic Rhinosinusitis with Nasal Polyps

Expiration Date: December 10, 2022

Educational Provider: University of Cincinnati


New Biologics Agents in CRSwNP

Expiration Date: May 2, 2023

Educational Provider: Integrity Continuing Education, Inc.


GSK Medical will be attending the following key congresses. Please visit us at our scientific booth or view our scientific information.

Meet Us

AAAAI | Feb 25-28, 2022 | Phoenix, AZ

ATS | May 13-18, 2022 | San Francisco, CA

AAOA | Sep 9-11, 2022 | Philadelphia, PA

AAO-HNSF | Sep 10-14, 2022 | Philadelphia, PA

AAFP | Sep 20-24, 2022 | Washington, DC

CHEST | Oct 16-19, 2022 | Nashville, TN

ACAAI | Nov 10-14, 2022 | Louisville, KY

View our ongoing, innovative research with respiratory diseases.

ASTHMA Phase I Phase II Phase III

Placebo-Controlled Efficacy and Safety Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832

A Study of GSK3511294 in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103

A Study of GSK3511294 Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

NCT03248128
COPD Phase I Phase II Phase III

MATINEE: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

NCT04133909
VIRAL COPD EXACERBATIONS Phase I Phase II Phase III

Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics

NCT04585009

View information about our respiratory portfolio of products including prescribing information, and material safety sheets.

Please see below for disease state videos, and webinars related to respiratory illnesses.

COPD

Patients Presenting with Dyspnea With Dr. Vega (4:42 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Assessment of Patient Presenting With Dyspnea With Dr. Vega (4:18 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Patient Presenting with Recent Exacerbations with Dr. Skolnik (4:03 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Assessment of a Patient Presenting with Recent Exacerbations with Dr. Skolnik (9:29 duration)

© American Academy of Family Physicians 2021. All rights reserved.

Intervention Opportunities in COPD Management Infographic

© American Academy of Family Physicians 2021. All rights reserved.

COPDetective Interactive Game


Asthma

Role of LAMAs in Asthma With Dr. Spahn (6:12)


The Role of Eosinophils and Their Potential Heterogeneity in Airways Disease (50:00)

Asthma Ascent Escape Room Game
(An Interactive Game)

Clinical Profiles in Severe Eosinophilic Asthma (60:58)

EGPA

EGPA: Pathogenesis, Diagnosis, and Management With Dr. Wechsler (28:06)

EGPA Mechanism of Disease (3:54)

HES

Investigating the Role of Eosinophils in Health, Airway Diseases, and Hypereosinophilic Disorders (40:56)

Current Understanding of Hypereosinophilic Syndrome (HES): A Rare Inflammatory Eosinophilic Disease (19:53)

HES Mechanism of Disease (6:24)

CRSwNP

Chronic Rhinosinusitis and Comorbid Conditions: Update on Etiology and Treatment (43:25)

Chronic Rhinosinusitis, Nasal Polyps and Asthma: The Unified Airway (50:20)

Revealing Key Pathophysiology to Guide Future Management of CRS/CRSwNP (53:25)

GSK Respiratory Medical Team attends several key medical congresses. You can access presentations, posters, and symposia material below.

ATS 2022

May 13-18, 2022 | San Francisco, CA

AAAAI 2022

Feb 25–28, 2022 | Phoenix, AZ

ACAAI 2021

 Nov 4-8, 2021 | New Orleans, LA

CHEST 2021

Oct 17-20, 2021 | Orlando, FL | Virtual

AAOA 2021

Oct 16-21, 2021 | Virtual

AAO-HNSF 2021

Oct 3-6, 2021 | Los Angeles, CA

ARS 2021

Oct 1-2, 2021 | Los Angeles, CA

AAFP 2021

Sep 28-Oct 2, 2021 | Virtual

Please see below for disease state audio podcasts related to respiratory illnesses.

Uncontrolled Asthma: Unmet Needs With Dr. Ditto (21:44)

Uncontrolled Asthma: Putting Guidelines into Practice With Dr. Ditto (19:18)

Uncontrolled Asthma: Unmet Need With Drs. Soler and Hannania (12:30)

Uncontrolled Asthma: Practical Considerations for Primary Care With Ditto (22:03)

A Look at Diagnostic Challenges for severe Asthma (11:29)

Obstacles of diagnosing severe and/or uncontrolled asthma (reachmd.com)

Evaluating Eosinophilic Disorders: EGPA & HES (13:59)

How to better distinguish between EGPA and HES. (reachmd.com)